IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study
Chen, Nan1; Wu, Xiongfei2; Ding, Xiaoqiang3; Mei, Changlin4; Fu, Ping5; Jiang, Gengru6; Li, Xuemei7; Chen, Jianghua8; Liu, Bicheng9; La, Yan10; Hou, Fanfan11; Ni, Zhaohui12; Fu, Junzhou13; Xing, Changying14; Yu, Xuequing15; Huang, Chaoxing16; Zuo, Li17; Wang, Li18; Hunter, John19; Dillon, Maureen19; Plone, Melissa19; Neylan, John19
关键词clinical study haemodialysis hyperphosphataemia placebo sevelamer carbonate
刊名NEPHROLOGY DIALYSIS TRANSPLANTATION
2014
DOI10.1093/ndt/gft232
29期:1页:152-160
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Transplantation ; Urology & Nephrology
研究领域[WOS]Transplantation ; Urology & Nephrology
关键词[WOS]CHRONIC KIDNEY-DISEASE ; FREE PHOSPHATE BINDER ; CHRONIC-RENAL-FAILURE ; PARATHYROID-HORMONE ; MINERAL METABOLISM ; LANTHANUM CARBONATE ; DIALYSIS OUTCOMES ; PRACTICE PATTERNS ; CROSSOVER DESIGN ; CALCIUM ACETATE
英文摘要

Hyperphosphataemia in patients with advanced chronic kidney disease (CKD) is associated with adverse outcomes, including vascular calcification and higher mortality rates. While phosphate lowering is an integral aspect of CKD management, the efficacy and safety of phosphate binders in a contemporary cohort of Chinese haemodialysis patients (who have different genetics and dietary patterns than other populations) has not been previously described. Moreover, sparse data are available on strategies for optimal dose titration when transitioning from a calcium-based to a polymer-based phosphate binder.

This randomized, double-blind, dose-titration study compared sevelamer carbonate (starting dose 800 mg three times daily) with placebo over 8 weeks duration in Chinese CKD patients on haemodialysis. Patients were required to be using calcium-based binders prior to study start.

In all, 205 patients were randomized (sevelamer, n 135; placebo, n 70); mean age was 48.6 years, 61 were male and the mean time on dialysis was 4.4 years. The mean serum phosphorus decreased significantly in patients treated with sevelamer carbonate [change 0.69 0.64 mmol/L (2.14 1.98 mg/dL)] but remained persistently elevated with placebo [change 0.06 0.57 mmol/L (0.19 1.76 mg/dL)] (P 0.0001). When compared with placebo, sevelamer carbonate treatment resulted in statistically significant greater mean reductions from baseline in serum total (17.1 versus 3.3) and low-density lipoprotein cholesterol (33.5 versus7.6) (P 0.0001 for both). Sevelamer carbonate was well tolerated with 96 adherence compared with 97 adherence in the placebo arm. Overall, adverse events experienced by patients in the sevelamer carbonate and placebo treatment groups were similar and consistent with their underlying renal disease.

This study demonstrated that hyperphosphataemia developed quickly following the cessation of phosphate binders and remained persistently elevated in end-stage CKD in the placebo-treated group. Gradually titrating up sevelamer carbonate from an initial dose of 2.4 g/day to an average daily dose of 7.1 2.5 g/day was well tolerated, safe and efficacious in contemporary Chinese haemodialysis patients.

语种英语
WOS记录号WOS:000330664000021
项目编号SVCARB03808
资助机构Sanofi ; Genzyme Corporation
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60926
专题北京大学第一临床医学院
作者单位1.Genzyme Corp, Cambridge, MA USA
2.Shanghai Ruijin Hosp, Shanghai, Peoples R China
3.Southwest Hosp, Chongqing, Peoples R China
4.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
5.Shanghai Changzheng Hosp, Shanghai, Peoples R China
6.Peking Univ, Hosp 1, Beijing 100871, Peoples R China
7.Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
8.Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
9.Qingdao Municipal Hosp, Eastern Hosp, Qingdao, Peoples R China
10.Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
11.Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China
12.Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China
13.Beijing Union Med Coll Hosp, Beijing, Peoples R China
14.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
15.Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
16.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai 200030, Peoples R China
17.Guangzhou First Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China
18.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
19.Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China
推荐引用方式
GB/T 7714
Chen, Nan,Wu, Xiongfei,Ding, Xiaoqiang,et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION,2014,29(1):152-160.
APA Chen, Nan.,Wu, Xiongfei.,Ding, Xiaoqiang.,Mei, Changlin.,Fu, Ping.,...&Neylan, John.(2014).Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.NEPHROLOGY DIALYSIS TRANSPLANTATION,29(1),152-160.
MLA Chen, Nan,et al."Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study".NEPHROLOGY DIALYSIS TRANSPLANTATION 29.1(2014):152-160.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Nan]的文章
[Wu, Xiongfei]的文章
[Ding, Xiaoqiang]的文章
百度学术
百度学术中相似的文章
[Chen, Nan]的文章
[Wu, Xiongfei]的文章
[Ding, Xiaoqiang]的文章
必应学术
必应学术中相似的文章
[Chen, Nan]的文章
[Wu, Xiongfei]的文章
[Ding, Xiaoqiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。